Circulating Calprotectin (cCLP) in autoimmune diseases

Ometto, 2017, Calprotectin in rheumatic diseases, Exp Biol Med (Maywood), 242, 859, 10.1177/1535370216681551 Romand, 2019, Systemic calprotectin and chronic inflammatory rheumatic diseases, Joint Bone Spine, 86, 691, 10.1016/j.jbspin.2019.01.003 Inciarte-Mundo, 2022, From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis, Front Immunol, 13, 1001025, 10.3389/fimmu.2022.1001025 Marenholz, 2006, An update of the S100 nomenclature, Biochim Biophys Acta, 1763, 1282, 10.1016/j.bbamcr.2006.07.013 Vogl, 2012, Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes, Int J Mol Sci, 13, 2893, 10.3390/ijms13032893 Gilliam, 2013, Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis, Pediatr Rheumatol Online J, 11, 31, 10.1186/1546-0096-11-31 Vogl, 2004, MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes, Blood., 104, 4260, 10.1182/blood-2004-02-0446 Steinbakk, 1990, Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin, Lancet., 336, 763, 10.1016/0140-6736(90)93237-J Sohnle, 2000, Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14), J Infect Dis, 182, 1272, 10.1086/315810 Korndorfer, 2007, The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins, J Mol Biol, 370, 887, 10.1016/j.jmb.2007.04.065 Naess-Andresen, 1995, Calcium binding and concomitant changes in the structure and heat stability of calprotectin (L1 protein), Clin Mol Pathol, 48, M278, 10.1136/mp.48.5.M278 Stephan, 2016, Calcium-induced Tetramerization and Zinc Chelation Shield Human Calprotectin from Degradation by Host and Bacterial Extracellular Proteases, Chem Sci, 7, 1962, 10.1039/C5SC03287C Lee, 2017, Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review, Autoimmun Rev, 16, 1160, 10.1016/j.autrev.2017.09.012 Drury, 2021, Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation, Cell Mol Gastroenterol Hepatol, 12, 321, 10.1016/j.jcmgh.2021.03.002 Kim, 2021, An update on the pathogenic role of neutrophils in systemic juvenile idiopathic arthritis and adult-onset still’s disease, Int J Mol Sci, 22, 10.3390/ijms222313038 Grayson, 2016, At the Bench: neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases, J Leukoc Biol, 99, 253, 10.1189/jlb.5BT0615-247R Papayannopoulos, 2018, Neutrophil extracellular traps in immunity and disease, Nat Rev Immunol, 18, 134, 10.1038/nri.2017.105 Vogl, 2007, Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock, Nat Med, 13, 1042, 10.1038/nm1638 Urban, 2009, Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans, PLoS Pathog, 5, 10.1371/journal.ppat.1000639 Ehrchen, 2009, The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer, J Leukoc Biol, 86, 557, 10.1189/jlb.1008647 Frangou, 2019, An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment, Autoimmun Rev, 18, 751, 10.1016/j.autrev.2019.06.011 Loser, 2010, The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells, Nat Med, 16, 713, 10.1038/nm.2150 Sarrand, 2022, The Involvement of Alarmins in the Pathogenesis of Sjogren’s Syndrome, Int J Mol Sci, 23, 10.3390/ijms23105671 Averill, 2011, S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation, Circulation., 123, 1216, 10.1161/CIRCULATIONAHA.110.985523 Carlucci, 2018, Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus, JCI Insight, 3, 10.1172/jci.insight.99276 Bisoendial, 2011, Critical determinants of cardiovascular risk in rheumatoid arthritis, Curr Pharm Des, 17, 21, 10.2174/138161211795049741 Doring, 2017, Neutrophil extracellular traps in atherosclerosis and atherothrombosis, Circ Res, 120, 736, 10.1161/CIRCRESAHA.116.309692 Ehlermann, 2006, Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products, Cardiovasc Diabetol, 5, 6, 10.1186/1475-2840-5-6 Kunutsor, 2018, Plasma calprotectin and risk of cardiovascular disease: findings from the PREVEND prospective cohort study, Atherosclerosis., 275, 205, 10.1016/j.atherosclerosis.2018.06.817 Scherer, 2020, The etiology of rheumatoid arthritis, J Autoimmun, 110, 10.1016/j.jaut.2019.102400 Aletaha, 2010, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 69, 1580, 10.1136/ard.2010.138461 Lood, 2016, Platelet-Derived S100A8/A9 and cardiovascular disease in systemic lupus erythematosus, Arthritis Rheumatol, 68, 1970, 10.1002/art.39656 Carrion, 2013, IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts, Rheumatology (Oxford), 52, 2177, 10.1093/rheumatology/ket315 Hammer, 1995, A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis, Clin Exp Rheumatol, 13, 59 Abildtrup, 2015, Calprotectin as a biomarker for rheumatoid arthritis: a systematic review, J Rheumatol, 42, 760, 10.3899/jrheum.140628 Bae, 2017, Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis, Postgrad Med, 129, 531, 10.1080/00325481.2017.1319729 Hammer, 2007, Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis, Ann Rheum Dis, 66, 1093, 10.1136/ard.2006.064741 Jonsson, 2017, Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis, Ann Rheum Dis, 76, 2031, 10.1136/annrheumdis-2017-211695 Chevreau, 2018, Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis. Comment on ‘Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis’ by Jonsson et al, Ann Rheum Dis, 77, e84, 10.1136/annrheumdis-2017-212816 Brun, 1992, Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity, J Rheumatol, 19, 859 Garcia-Arias, 2013, Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort, Mol Diagn Ther, 17, 49, 10.1007/s40291-013-0016-9 Chen, 2009, Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis, Arthritis Res Ther, 11, R39, 10.1186/ar2645 Hammer, 2010, Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis, Ann Rheum Dis, 69, 150, 10.1136/ard.2008.103739 Schieir, 2017, Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis, Ann Rheum Dis, 76, 1396, 10.1136/annrheumdis-2016-210275 Choi, 2015, MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, Ann Rheum Dis, 74, 499, 10.1136/annrheumdis-2013-203923 Nordal, 2017, Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis, Arthritis Res Ther, 19, 3, 10.1186/s13075-016-1201-0 Andres Cerezo, 2011, Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis, Arthritis Res Ther, 13, R122, 10.1186/ar3426 Tweehuysen, 2018, Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis, RMD Open, 4, 10.1136/rmdopen-2018-000654 Hurnakova, 2016, Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission, PloS One, 11, 10.1371/journal.pone.0165498 Hurnakova, 2018, Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein, Clin Rheumatol, 37, 2055, 10.1007/s10067-018-4091-5 Inciarte-Mundo, 2015, Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants, Rheumatology (Oxford), 54, 2239 Gernert, 2022, Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy, Arthritis Res Ther, 24, 200, 10.1186/s13075-022-02887-7 Bettner, 2021, Combinations of Anticyclic Citrullinated Protein Antibody, Rheumatoid Factor, and Serum Calprotectin Positivity Are Associated With the Diagnosis of Rheumatoid Arthritis Within 3 Years, ACR Open Rheumatol, 3, 684, 10.1002/acr2.11309 Baraliakos, 2017, Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time, Rheumatology (Oxford), 56, 1162, 10.1093/rheumatology/kex081 Sokolova, 2020, A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations, Arthritis Res Ther, 22, 26, 10.1186/s13075-020-2111-8 Reece, 1999, Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis, Arthritis Rheum, 42, 1481, 10.1002/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E Cypers, 2016, Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis, Ann Rheum Dis, 75, 1357, 10.1136/annrheumdis-2015-208025 Romand, 2021, Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: Results from the DESIR cohort, Joint Bone Spine, 88, 10.1016/j.jbspin.2020.08.003 Jarlborg, 2020, Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis, Arthritis Res Ther, 22, 105, 10.1186/s13075-020-02190-3 Ma, 2020, Calprotectin in spondyloarthritis: a systematic review and meta-analysis, Int Immunopharmacol, 88, 10.1016/j.intimp.2020.106948 Sakellariou, 2019, Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study, Clin Exp Rheumatol, 37, 429 Vanh, 2019, Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies, J Rheumatol, 46, 215, 10.3899/jrheum.180432 Cheng, 2022, Serum Calprotectin level Is independently associated with carotid plaque presence in patients with Psoriatic Arthritis, Front Med (Lausanne), 9 Turina, 2014, Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis, Arthritis Res Ther, 16, 413, 10.1186/s13075-014-0413-4 Rademacher, 2019, Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis, Rheumatology (Oxford), 58, 1556, 10.1093/rheumatology/kez025 Fautrel, 2002, Proposal for a new set of classification criteria for adult-onset still disease, Medicine (Baltimore), 81, 194, 10.1097/00005792-200205000-00003 Feist, 2018, Mechanisms, biomarkers and targets for adult-onset Still’s disease, Nat Rev Rheumatol, 14, 603, 10.1038/s41584-018-0081-x Martini, 2019, Toward new classification Criteria for Juvenile Idiopathic Arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus, J Rheumatol, 46, 190, 10.3899/jrheum.180168 La, 2021, Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis, RMD Open, 7, 10.1136/rmdopen-2021-001646 Ma, 2022, Enhanced type I interferon signature induces neutrophil extracellular traps enriched in mitochondrial DNA in adult-onset Still’s disease, J Autoimmun, 127, 10.1016/j.jaut.2022.102793 Holzinger, 2012, The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis, Ann Rheum Dis, 71, 974, 10.1136/annrheumdis-2011-200598 Kim, 2016, TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations, Int J Mol Sci, 17, 10.3390/ijms17081342 Aljaberi, 2020, The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis, Pediatr Rheumatol Online J, 18, 7, 10.1186/s12969-020-0398-2 Romano, 2021, Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis, Clin Exp Rheumatol, 39, 1132, 10.55563/clinexprheumatol/5tckci Keskitalo, 2022, Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center, Pediatr Rheumatol Online J, 20, 42, 10.1186/s12969-022-00701-x Park, 2022, MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever, Rheumatology (Oxford), 61, 3082, 10.1093/rheumatology/keab729 Gerss, 2012, Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study, Ann Rheum Dis, 71, 1991, 10.1136/annrheumdis-2012-201329 Rothmund, 2014, Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis, Arthritis Care Res (Hoboken), 66, 949, 10.1002/acr.22248 Anink, 2015, MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis, Arthritis Res Ther, 17, 200, 10.1186/s13075-015-0723-1 Kitching, 2020, ANCA-associated vasculitis, Nat Rev Dis Primers, 6, 71, 10.1038/s41572-020-0204-y Trivioli, 2022, Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management, Nat Rev Rheumatol, 18, 559, 10.1038/s41584-022-00819-y Robson, 2015, Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials, Ann Rheum Dis, 74, 177, 10.1136/annrheumdis-2013-203927 Kronbichler, 2015, Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis, Eur J Clin Invest, 45, 346, 10.1111/eci.12410 Chung, 2021, 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Arthritis Rheumatol, 73, 1366, 10.1002/art.41773 Guchelaar, 2021, The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis, Autoimmun Rev, 20, 10.1016/j.autrev.2020.102716 Bossuyt, 2017, Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis, Nat Rev Rheumatol, 13, 683, 10.1038/nrrheum.2017.140 Tomasson, 2012, Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis, Rheumatology (Oxford), 51, 100, 10.1093/rheumatology/ker280 Van Hoovels, 2017, Serum calprotectin as promising diagnostic aid in predicting relapse in proteinase 3-antineutrophil cytoplasmatic antibodies-associated vasculitis, J Lab Precis Med, 2 Pepper, 2013, Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis, Kidney Int, 83, 1150, 10.1038/ki.2013.2 Martinez Valenzuela, 2018, Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis, PloS One, 13, 10.1371/journal.pone.0205982 Michailidou, 2022, Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis, Arthritis Res Ther, 24, 160, 10.1186/s13075-022-02849-z Bai, 2022, The potential pathogenic roles of S100A8/A9 and S100A12 in patients with MPO-ANCA-positive vasculitis, BMC Immunol, 23, 42, 10.1186/s12865-022-00513-4 Pepper, 2017, Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Arthritis Rheumatol, 69, 185, 10.1002/art.39814 Lythgoe, 2022, Classification of systemic lupus erythematosus in children and adults, Clin Immunol, 234, 10.1016/j.clim.2021.108898 Aringer, 2019, 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Ann Rheum Dis, 78, 1151, 10.1136/annrheumdis-2018-214819 Kiriakidou, 2020, Systemic Lupus Erythematosus, Ann Intern Med, 172, 10.7326/AITC202006020 Mageau, 2019, The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study, Autoimmun Rev, 18, 733, 10.1016/j.autrev.2019.05.011 Gonzalez, 2021, Systemic lupus erythematosus: the search for the ideal biomarker, Lupus., 30, 181, 10.1177/0961203320979051 Davies, 2020, Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment, RMD Open, 6, 10.1136/rmdopen-2020-001257 Hakkim, 2010, Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis, Proc Natl Acad Sci U S A, 107, 9813, 10.1073/pnas.0909927107 Leffler, 2012, Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease, J Immunol, 188, 3522, 10.4049/jimmunol.1102404 Haga, 1993, Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity, Lupus., 2, 47, 10.1177/096120339300200108 Soyfoo, 2009, Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus, J Rheumatol, 36, 2190, 10.3899/jrheum.081302 Turnier, 2017, Urine S100 proteins as potential biomarkers of lupus nephritis activity, Arthritis Res Ther, 19, 242, 10.1186/s13075-017-1444-4 Tyden, 2017, Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus, Lupus., 26, 139, 10.1177/0961203316655208 Sumova, 2019, Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study, Rheumatol Int, 39, 469, 10.1007/s00296-018-4190-2 Kim, 2022, S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus, Front Immunol, 13 Homa-Mlak, 2022, Serum Calprotectin - a NET Product - as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland, Med Sci Monit, 28, 10.12659/MSM.936534 Tydén, 2017, Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus, RMD Open, 3, 000508, 10.1136/rmdopen-2017-000508 Betteridge, 2016, Myositis-specific autoantibodies: an important tool to support diagnosis of myositis, J Intern Med, 280, 8, 10.1111/joim.12451 Lundberg, 2017, 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups, Ann Rheum Dis, 76, 1955, 10.1136/annrheumdis-2017-211468 Cerezo, 2020, Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis, Curr Opin Rheumatol, 32, 534, 10.1097/BOR.0000000000000744 Nistala, 2013, Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis, Arthritis Res Ther, 15, R131, 10.1186/ar4311 Andres Cerezo, 2019, Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis, Cytokine., 116, 13, 10.1016/j.cyto.2018.12.023 Duvvuri, 2020, Neutrophil extracellular traps in tissue and periphery in Juvenile Dermatomyositis, Arthritis Rheumatol, 72, 348, 10.1002/art.41078 Cappelletti, 2014, Autophagy, inflammation and innate immunity in inflammatory myopathies, PloS One, 9, 10.1371/journal.pone.0111490 Lou, 2020, Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease, BMC Pulm Med, 20, 196, 10.1186/s12890-020-01226-3 Mariette, 2018, Primary Sjogren’s Syndrome, N Engl J Med, 378, 931, 10.1056/NEJMcp1702514 Shiboski, 2017, 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts, Ann Rheum Dis, 76, 9, 10.1136/annrheumdis-2016-210571 Jung, 2021, Salivary Biomarkers in Patients with Sjogren’s Syndrome-A Systematic Review, Int J Mol Sci, 22, 10.3390/ijms222312903 Nicaise, 2017, Phagocyte-specific S100A8/A9 is upregulated in primary Sjogren’s syndrome and triggers the secretion of pro-inflammatory cytokines in vitro, Clin Exp Rheumatol, 35, 129 Cuida, 1997, Indicators of salivary gland inflammation in primary Sjogren’s syndrome, Eur J Oral Sci, 105, 228, 10.1111/j.1600-0722.1997.tb00205.x Nordal, 2014, Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjogren’s syndrome, Scand J Rheumatol, 43, 76, 10.3109/03009742.2013.848930 Liu, 2014, TLR2 and TLR4 in autoimmune diseases: a comprehensive review, Clin Rev Allergy Immunol, 47, 136, 10.1007/s12016-013-8402-y Katz, 2004, Receptor of advanced glycation end product (RAGE) expression in the minor salivary glands of patients with Sjogren’s syndrome: a preliminary study, Scand J Rheumatol, 33, 174, 10.1080/03009740310004775 Brun, 1994, Sjogren’s syndrome in inflammatory rheumatic diseases: analysis of the leukocyte protein calprotectin in plasma and saliva, Scand J Rheumatol, 23, 114, 10.3109/03009749409103041 Jazzar, 2018, Salivary S100A8/A9 in Sjogren’s syndrome accompanied by lymphoma, J Oral Pathol Med, 47, 900, 10.1111/jop.12763 Balarini, 2016, Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjogren’s syndrome, Clin Exp Rheumatol, 34, 1006 van den Hoogen, 2013, 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative, Arthritis Rheum, 65, 2737, 10.1002/art.38098 Kotsiou, 2021, Calprotectin in Lung Diseases, Int J Mol Sci, 22, 10.3390/ijms22041706 Damoiseaux, 2022, Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application, J Transl Autoimmun, 5, 10.1016/j.jtauto.2022.100141 Smeets, 2020, Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels, Autoimmun Rev, 19, 10.1016/j.autrev.2020.102515 Xu, 2013, Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities, Clin Rheumatol, 32, 1501, 10.1007/s10067-013-2305-4 van Bon, 2014, Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype, Ann Rheum Dis, 73, 1585, 10.1136/annrheumdis-2013-205013 Machahua, 2021, Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open, Respir Res, 8, 10.1136/bmjresp-2020-000827 Tanaka, 2021, Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis, Respir Investig, 59, 827, 10.1016/j.resinv.2021.05.008 Ng, 2017, Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies, Lancet., 390, 2769, 10.1016/S0140-6736(17)32448-0 Guan, 2019, A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease, J Immunol Res, 2019, 7247238, 10.1155/2019/7247238 Jukic, 2021, Calprotectin: from biomarker to biological function, Gut., 70, 1978, 10.1136/gutjnl-2021-324855 Fukunaga, 2018, Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization, Int J Mol Med, 41, 107 Chang, 2015, Disease monitoring in inflammatory bowel disease, World J Gastroenterol, 21, 11246, 10.3748/wjg.v21.i40.11246 Mumolo, 2018, From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting, World J Gastroenterol, 24, 3681, 10.3748/wjg.v24.i33.3681 Mori, 2021, Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease, Kurume Med J, 66, 209, 10.2739/kurumemedj.MS664009 Kalla, 2016, Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases, Am J Gastroenterol, 111, 1796, 10.1038/ajg.2016.342 Okada, 2019, Serum S100A8/A9 as a Potentially Sensitive Biomarker for Inflammatory Bowel Disease, Lab Med, 50, 370, 10.1093/labmed/lmz003 Okada, 2020, Circulating S100A8/A9 is potentially a biomarker that could reflect the severity of experimental colitis in rats, Heliyon, 6, 10.1016/j.heliyon.2020.e03470 Meuwis, 2013, Serum calprotectin as a biomarker for Crohn’s disease, J Crohns Colitis, 7, e678, 10.1016/j.crohns.2013.06.008 Mortensen, 2022, A Specific Calprotectin Neo-epitope [CPa9-HNE] in Serum from Inflammatory Bowel Disease Patients Is Associated with Neutrophil Activity and Endoscopic Severity, J Crohns Colitis, 16, 1447, 10.1093/ecco-jcc/jjac047 Gilhus, 2015, Myasthenia gravis: subgroup classification and therapeutic strategies, Lancet Neurol, 14, 1023, 10.1016/S1474-4422(15)00145-3 Stascheit, 2021, Calprotectin as potential novel biomarker in myasthenia gravis, J Transl Autoimmun, 4, 10.1016/j.jtauto.2021.100111 Bogumil, 1998, Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis, Neurosci Lett, 247, 195, 10.1016/S0304-3940(98)00263-8 Wu, 2018, S100A8/A9 induces microglia activation and promotes the apoptosis of oligodendrocyte precursor cells by activating the NF-kappaB signaling pathway, Brain Res Bull, 143, 234, 10.1016/j.brainresbull.2018.09.014 Stascheit, 2021, Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-A Potential Novel Biomarker of Disease Activity, Front Neurol, 12, 10.3389/fneur.2021.723009 Mathey, 2015, Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype, J Neurol Neurosurg Psychiatry, 86, 973, 10.1136/jnnp-2014-309697 Kim, 2020, Proinflammatory effects of Calprotectin in Graves’ Orbitopathy, Ocul Immunol Inflamm, 28, 156, 10.1080/09273948.2018.1547835 Schmidt, 2013, Pemphigoid diseases, Lancet., 381, 320, 10.1016/S0140-6736(12)61140-4 Akbarzadeh, 2016, Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid, J Dermatol Sci, 81, 165, 10.1016/j.jdermsci.2015.12.001 Tsirouki, 2018, A Focus on the Epidemiology of Uveitis, Ocul Immunol Inflamm, 26, 2, 10.1080/09273948.2016.1196713 Song, 2019, The Expression of Calprotectin and Factors in TLR4/NF-kappaB/MyD88 Pathway in Patients with Idiopathic Acute Anterior Uveitis, Ocul Immunol Inflamm, 27, 1144, 10.1080/09273948.2018.1485956 Wang, 2016, S100A8 promotes migration and infiltration of inflammatory cells in acute anterior uveitis, Sci Rep, 6, 36140, 10.1038/srep36140 So, 2017, Inflammation in gout: mechanisms and therapeutic targets, Nat Rev Rheumatol, 13, 639, 10.1038/nrrheum.2017.155 Vedder, 2020, Neutrophil activation identifies patients with active polyarticular gout, Arthritis Res Ther, 22, 148, 10.1186/s13075-020-02244-6 Perez-Ruiz, 2014, Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout, Ann Rheum Dis, 73, 177, 10.1136/annrheumdis-2012-202421 Stamp, 2011, Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?, J Rheumatol, 38, 1462, 10.3899/jrheum.110273 Kuo, 2015, Global epidemiology of gout: prevalence, incidence and risk factors, Nat Rev Rheumatol, 11, 649, 10.1038/nrrheum.2015.91 Hahn, 2016, Neutrophils and neutrophil extracellular traps orchestrate initiation and resolution of inflammation, Clin Exp Rheumatol, 34, 6 Desai, 2016, PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling, Eur J Immunol, 46, 223, 10.1002/eji.201545605 Hammer, 2022, Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study, RMD Open, 8, 10.1136/rmdopen-2022-002348 Holzinger, 2014, Myeloid-related proteins 8 and 14 contribute to monosodium urate monohydrate crystal-induced inflammation in gout, Arthritis Rheumatol, 66, 1327, 10.1002/art.38369 Neogi, 2015, 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 74, 1789, 10.1136/annrheumdis-2015-208237